Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 3/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 2/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | MAT2A | P31153 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20848711 | 0.96 | CYP2C9 (0.33) | CYP2C9SCN9AALOX5APFEN1DGAT1 | |
| SCHEMBL20848784 | 0.96 | ALOX5AP (0.34) | CYP2C9SCN9AALOX5APFEN1DGAT1 | |
| SCHEMBL20848708 | 0.96 | ALOX5AP (0.34) | CYP2C9SCN9AALOX5APFEN1DGAT1 | |
| SCHEMBL20848975 | 0.96 | PTGER4 (0.36) | CYP2C9SCN9AALOX5APFEN1KIF11 | |
| SCHEMBL22985356 | 0.95 | NSD2 (0.33) | KIF11NSD2CTSSCTSK | |
| SCHEMBL21399456 | 0.93 | KIF11 (0.35) | DGAT1SOAT1KCNH2KIF11ELANE | |
| SCHEMBL20848787 | 0.92 | PTGER4 (0.37) | CYP2C9SCN9AALOX5APFEN1DGAT1 | |
| SCHEMBL20848698 | 0.92 | PTGER4 (0.37) | CYP2C9SCN9AALOX5APFEN1DGAT1 | |
| SCHEMBL22985195 | 0.91 | ALOX5AP (0.38) | SCN9AALOX5APFEN1DGAT1SOAT1 | |
| SCHEMBL22985243 | 0.91 | NSD2 (0.33) | KIF11NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10978646-B2 | Organic molecules for use in optoelectronic devices | CYNORA GMBH (DE) | 2021-04-13 | — | — | US | disclosed |
| US-20190097141-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10978646-B2 | Organic molecules for use in optoelectronic devices | OCIAD2, OCIAD1, POU2F1 | CYP2C9 725/4885SCN9A 1664/4885ALOX5AP 3630/4885 |
| US-20190097141-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | OCIAD2, OCIAD1, POU2F1 | CYP2C9 725/4885SCN9A 1664/4885ALOX5AP 3630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.